Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Conmed (CNMD) Asset Writedowns and Impairment (2021)

Conmed filings provide 1 years of Asset Writedowns and Impairment readings, the most recent being $899000.0 for Q3 2021.

On a quarterly basis, Asset Writedowns and Impairment changed N/A to $899000.0 in Q3 2021 year-over-year; TTM through Dec 2022 was $899000.0, a N/A change, with the full-year FY2025 number at $363000.0, changed N/A from a year prior.
Asset Writedowns and Impairment hit $899000.0 in Q3 2021 for Conmed.
In the past five years, Asset Writedowns and Impairment ranged from a high of $899000.0 in Q3 2021 to a low of $899000.0 in Q3 2021.